Latest research on Quetiapine

Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.

Latest findings

More research is needed to ascertain the safety and dosing of Quetiapine, especially in the young population. [source, 2001]
Quetiapine was developed to mimic the receptor profile and the pharmacology of Clozapine. [source, 2001]
There are several reports of the use of Quetiapine in the elderly for the treatment of psychosis with PD. [source, 2001]
No controlled studies are currently available for Quetiapine use in patients with the diagnosis of schizophrenia only. [source, 2001]
Weight gain and EPS occur at low rates with Quetiapine use. [source, 2001]
Quetiapine should be used as a first-line agent for psychosis associated with PD. [source, 2001]
Likewise, few data are available for comorbid substance abuse and the treatment of schizophrenia with Quetiapine. [source, 2001]
Very little data on Quetiapine use in treatment-resistant schizophrenia are available. [source, 2001]
There is a recent publication of a cross-sectional study that reports better subjective response measured with the DAI-30 in patients treated with new antipsychotics compared to conventional antipsychotics, but not difference between different new antipsychotics (Risperidone, Olanzapine, Quetiapine and Clozapine) [40]. [source, 2001]
The approval of the new compounds by the US Food and Drug Administration (FDA) (first Risperidone, then Olanzapine, Quetiapine, and finally Ziprasidone) fails to recognize the significant number of drugs that nearly reached general approval, but failed for safety or efficacy reasons. [source, 2000]